ProShare Advisors
AVIR icon

ProShare Advisors’s Atea Pharmaceuticals AVIR Stock Holding History

ProShare Advisors’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$55.4K Sell
11,907
-1,731
-13% -$8.61K ﹤0.01% 1833
2026
Q1 		$73.4K Sell
13,638
-2,802
-17% -$12.9K ﹤0.01% 1749
2025
Q4 		$58.7K Buy
16,440
+506
+3% +$1.61K ﹤0.01% 1940
2025
Q3 		$46.2K Sell
15,934
-2,978
-16% -$10.2K ﹤0.01% 1941
2025
Q2 		$68.1K Sell
18,912
-1,602
-8% -$4.78K ﹤0.01% 1947
2025
Q1 		$61.3K Sell
20,514
-5,219
-20% -$16.3K ﹤0.01% 1925
2024
Q4 		$86.2K Buy
25,733
+6,163
+31% +$20.5K ﹤0.01% 2099
2024
Q3 		$65.6K Buy
19,570
+4,104
+27% +$14.9K ﹤0.01% 1946
2024
Q2 		$51.2K Sell
15,466
-4,205
-21% -$15.7K ﹤0.01% 1746
2024
Q1 		$79.5K Buy
19,671
+1,651
+9% +$6.46K ﹤0.01% 1856
2023
Q4 		$55K Buy
18,020
+2,609
+17% +$7.9K ﹤0.01% 1850
2023
Q3 		$46.2K Buy
15,411
+45
+0.3% +$153 ﹤0.01% 1723
2023
Q2 		$57.5K Buy
15,366
+607
+4% +$2.27K ﹤0.01% 1757
2023
Q1 		$49.4K Sell
14,759
-1,948
-12% -$7.9K ﹤0.01% 1672
2022
Q4 		$80.4K Buy
16,707
+1,291
+8% +$6.53K ﹤0.01% 1689
2022
Q3 		$88K Buy
15,416
+361
+2% +$2.76K ﹤0.01% 1586
2022
Q2 		$108K Sell
15,055
-5,666
-27% -$38.7K ﹤0.01% 1602
2022
Q1 		$150K Sell
20,721
-5,104
-20% -$34.7K ﹤0.01% 1953
2021
Q4 		$231K Buy
25,825
+17,551
+212% +$274K ﹤0.01% 1944
2021
Q3 		$290K Sell
8,274
-8,929
-52% -$248K ﹤0.01% 1579
2021
Q2 		$370K Buy
17,203
+13,097
+319% +$394K ﹤0.01% 1745
2021
Q1 		$254K Buy
+4,106
New +$277K ﹤0.01% 1895

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

ProShare Advisors's AVIR Position: Q2 2026 in Review

ProShare Advisors reduced its Atea Pharmaceuticals (AVIR) stake by 13% in Q2 2026, selling an estimated $8.61K and leaving 11,907 shares worth $55.4K. The position accounts for ﹤0.01% of the portfolio, ranked #1833.

ProShare Advisors first reported a position in AVIR in Q1 2021 and has held it in 22 quarters since. The position peaked at $370K in Q2 2021. 125 funds tracked by Wall St. Rank hold AVIR as of Q2 2026.

  • ProShare Advisors held 11,907 shares of Atea Pharmaceuticals worth $55.4K as of Q2 2026.
  • ProShare Advisors sold 1,731 Atea Pharmaceuticals shares in Q2 2026, an estimated $8.61K.
  • Atea Pharmaceuticals made up ﹤0.01% of ProShare Advisors's portfolio in Q2 2026, its #1833 holding.
  • ProShare Advisors first reported a position in Atea Pharmaceuticals in Q1 2021 and has held it in 22 quarters since.
  • ProShare Advisors's Atea Pharmaceuticals position peaked at $370K in Q2 2021.
  • 125 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q2 2026.

Based on ProShare Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.